Silco Pharmaceuticals Statistics

Total Valuation

Silco Pharmaceuticals has a market cap or net worth of BDT 1.63 billion. The enterprise value is 1.58 billion.

Market Cap	1.63B
Enterprise Value	1.58B

Important Dates

The last earnings date was Thursday, October 31, 2024.

Earnings Date	Oct 31, 2024
Ex-Dividend Date	Dec 9, 2024

Share Statistics

Silco Pharmaceuticals has 103.81 million shares outstanding. The number of shares has increased by 1.20% in one year.

Current Share Class	n/a
Shares Outstanding	103.81M
Shares Change (YoY)	+1.20%
Shares Change (QoQ)	+0.57%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

The trailing PE ratio is 38.39.

PE Ratio	38.39
Forward PE	n/a
PS Ratio	3.89
PB Ratio	0.71
P/TBV Ratio	n/a
P/FCF Ratio	47.95
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.15, with an EV/FCF ratio of 46.44.

EV / Earnings	36.91
EV / Sales	3.74
EV / EBITDA	10.15
EV / EBIT	28.19
EV / FCF	46.44

Financial Position

The company has a current ratio of 3.48, with a Debt / Equity ratio of 0.00.

Current Ratio	3.48
Quick Ratio	1.57
Debt / Equity	0.00
Debt / EBITDA	0.07
Debt / FCF	0.31
Interest Coverage	81.88

Financial Efficiency

Return on equity (ROE) is 1.83% and return on invested capital (ROIC) is 1.50%.

Return on Equity (ROE)	1.83%
Return on Assets (ROA)	1.25%
Return on Capital (ROIC)	1.50%
Revenue Per Employee	1.36M
Profits Per Employee	137,482
Employee Count	311
Asset Turnover	0.15
Inventory Turnover	0.66

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.91% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-32.91%
50-Day Moving Average	18.17
200-Day Moving Average	19.37
Relative Strength Index (RSI)	37.03
Average Volume (20 Days)	290,259

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Silco Pharmaceuticals had revenue of BDT 421.83 million and earned 42.76 million in profits. Earnings per share was 0.41.

Revenue	421.83M
Gross Profit	126.47M
Operating Income	55.98M
Pretax Income	55.26M
Net Income	42.76M
EBITDA	151.72M
EBIT	55.98M
Earnings Per Share (EPS)	0.41

Full Income Statement

Balance Sheet

The company has 62.22 million in cash and 10.65 million in debt, giving a net cash position of 51.57 million or 0.50 per share.

Cash & Cash Equivalents	62.22M
Total Debt	10.65M
Net Cash	51.57M
Net Cash Per Share	0.50
Equity (Book Value)	2.35B
Book Value Per Share	21.96
Working Capital	761.61M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 97.30 million and capital expenditures -63.31 million, giving a free cash flow of 33.99 million.

Operating Cash Flow	97.30M
Capital Expenditures	-63.31M
Free Cash Flow	33.99M
FCF Per Share	0.33

Full Cash Flow Statement

Margins

Gross margin is 29.98%, with operating and profit margins of 13.27% and 10.14%.

Gross Margin	29.98%
Operating Margin	13.27%
Pretax Margin	13.10%
Profit Margin	10.14%
EBITDA Margin	35.97%
EBIT Margin	13.27%
FCF Margin	8.06%

Dividends & Yields

This stock pays an annual dividend of 0.10, which amounts to a dividend yield of 0.64%.

Dividend Per Share	0.10
Dividend Yield	0.64%
Dividend Growth (YoY)	-40.00%
Years of Dividend Growth	n/a
Payout Ratio	45.32%
Buyback Yield	-1.20%
Shareholder Yield	-0.56%
Earnings Yield	2.61%
FCF Yield	2.09%

Dividend Details

Stock Splits

The last stock split was on November 20, 2019. It was a forward split with a ratio of 1.1.

Last Split Date	Nov 20, 2019
Split Type	Forward
Split Ratio	1.1

Scores

Silco Pharmaceuticals has an Altman Z-Score of 4.25.

Altman Z-Score	4.25
Piotroski F-Score	n/a